Australian researchers have identified a gene that could hold the key to overcoming cancer‘s ability to evade the body’s immune system. A new study published in Cell Reports details how blocking the activity of the TAK1 gene appears to remove a protective mechanism used by cancer cells, potentially boosting the effectiveness of existing immunotherapies. The discovery, a collaboration between La Trobe University, the Olivia Newton-John Cancer Research institute, and WEHI, offers a promising new target in the ongoing fight against resistant tumors.
– WILDPIXEL/ ISTOCK – Archivo
MADRID, 22 Dic. (EUROPA PRESS) –
A new study suggests that blocking the activity of a gene called TAK1 could significantly improve the effectiveness of cancer immunotherapies. Researchers at La Trobe University in Australia have identified TAK1 as a key mechanism that helps cancer cells evade the body’s immune response, potentially limiting the success of these treatments. The findings were published in ‘Cell Reports’.
Immunotherapy has shown promise in treating various cancers, but its effectiveness varies among patients. Understanding why some tumors resist immune attack is crucial for developing more effective strategies. This research sheds light on one such resistance mechanism.
Working with collaborators at the Olivia Newton-John Cancer Research Institute (ONJCRI) and WEHI, also in Australia, the team discovered that TAK1 functions as a kind of “safety switch” within cancer cells. This switch protects them from the powerful signals sent by CD8+ T cells, a critical component of the immune system responsible for destroying cancer cells.
The identification of TAK1 came after a large-scale genetic analysis aimed at pinpointing genes that enable cancer cells to survive attacks from CD8+ T cells.
“TAK1 is known to promote cancer cell survival and block cell death, but we didn’t realize cancer cells were using this tactic to avoid being destroyed by the immune system,” said Dr. Anne Huber, a postdoctoral researcher at ONJCRI and affiliated with La Trobe University’s Cancer Medicine Faculty.
To test the importance of TAK1, researchers silenced the gene using CRISPR/Cas9 technology. In preclinical models with a functioning immune system, they observed that tumors lacking TAK1 exhibited significantly reduced growth, indicating that the immune system was better able to control the cancer cells.
Dr. Huber explained, “When we blocked TAK1, the immune signals generated by CD8+ T cells activated the cancer cells’ self-destruction pathways. Without TAK1, cancer cells lose a key protein, cFLIP, which normally prevents cell death, and become much more vulnerable to immune attack.”
By disabling TAK1, the research suggests it becomes easier for the immune system to eliminate cancer cells, offering hope for more potent treatment options in the future. The findings highlight a potential new target for cancer therapy.
Researchers believe that blocking TAK1 could enhance the effectiveness of existing immunotherapies by stripping tumors of this protective mechanism. They describe TAK1 as a buffer that allows cancer cells to withstand the strongest attacks from the immune system. Removing that buffer, they say, allows the tumor to succumb to the immune response.
The team plans to continue investigating ways to block TAK1, including utilizing innovative liquid nanoparticle technology, and will test the effectiveness of existing immunotherapies on cancer cells with blocked TAK1 activity.
